Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Syphilis | 6 | 2018 | 318 | 2.29 | Why? |
| Onygenales | 4 | 2018 | 11 | 1.84 | Why? |
| Sexually Transmitted Diseases | 5 | 2021 | 694 | 1.84 | Why? |
| Treponema pallidum | 3 | 2018 | 42 | 1.59 | Why? |
| Gonorrhea | 4 | 2021 | 315 | 1.39 | Why? |
| Pre-Exposure Prophylaxis | 3 | 2021 | 1138 | 1.18 | Why? |
| Sexual and Gender Minorities | 3 | 2018 | 1019 | 1.07 | Why? |
| Homosexuality, Male | 4 | 2021 | 1158 | 1.03 | Why? |
| Sexual Behavior | 4 | 2018 | 1322 | 0.92 | Why? |
| HIV Infections | 10 | 2021 | 11620 | 0.82 | Why? |
| Chlamydia Infections | 2 | 2021 | 248 | 0.79 | Why? |
| Macrolides | 3 | 2019 | 369 | 0.76 | Why? |
| Extensively Drug-Resistant Tuberculosis | 1 | 2019 | 87 | 0.75 | Why? |
| Microbiological Techniques | 2 | 2018 | 232 | 0.75 | Why? |
| Skin Pigmentation | 1 | 2019 | 98 | 0.74 | Why? |
| Chlamydia | 1 | 2018 | 47 | 0.73 | Why? |
| Clarithromycin | 1 | 2019 | 112 | 0.73 | Why? |
| Reagins | 1 | 2017 | 3 | 0.73 | Why? |
| Mouthwashes | 1 | 2021 | 432 | 0.62 | Why? |
| Helicobacter pylori | 1 | 2019 | 262 | 0.61 | Why? |
| Drug Resistance, Bacterial | 4 | 2019 | 1414 | 0.58 | Why? |
| Mycoses | 3 | 2018 | 589 | 0.58 | Why? |
| Ecosystem | 1 | 2020 | 776 | 0.58 | Why? |
| Antibodies, Bacterial | 1 | 2017 | 510 | 0.52 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.47 | Why? |
| HIV Seropositivity | 3 | 2018 | 320 | 0.44 | Why? |
| Mycobacterium tuberculosis | 1 | 2019 | 1164 | 0.41 | Why? |
| Interleukin-10 | 1 | 2017 | 1409 | 0.40 | Why? |
| Neisseria gonorrhoeae | 3 | 2021 | 142 | 0.38 | Why? |
| Syphilis Serodiagnosis | 2 | 2018 | 30 | 0.36 | Why? |
| Air Microbiology | 1 | 2018 | 1322 | 0.35 | Why? |
| Diet | 1 | 2020 | 2052 | 0.34 | Why? |
| Ascomycota | 2 | 2018 | 71 | 0.33 | Why? |
| Zoonoses | 1 | 2020 | 3034 | 0.31 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.31 | Why? |
| South Africa | 4 | 2018 | 3326 | 0.28 | Why? |
| Anti-Bacterial Agents | 4 | 2021 | 10083 | 0.27 | Why? |
| Mass Screening | 3 | 2018 | 8005 | 0.27 | Why? |
| Sociobiology | 1 | 2020 | 4 | 0.23 | Why? |
| Chlamydia trachomatis | 2 | 2021 | 172 | 0.22 | Why? |
| Belgium | 4 | 2021 | 2064 | 0.21 | Why? |
| Exercise | 1 | 2020 | 6771 | 0.20 | Why? |
| Rabies virus | 1 | 2019 | 92 | 0.19 | Why? |
| Rabies Vaccines | 1 | 2019 | 106 | 0.19 | Why? |
| DNA, Ribosomal Spacer | 1 | 2018 | 49 | 0.19 | Why? |
| Urease | 1 | 2017 | 10 | 0.18 | Why? |
| Trichomonas Infections | 1 | 2017 | 24 | 0.18 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.18 | Why? |
| Rabies | 1 | 2019 | 113 | 0.18 | Why? |
| Soil Microbiology | 1 | 2018 | 63 | 0.17 | Why? |
| Dermatomycoses | 1 | 2018 | 55 | 0.17 | Why? |
| Cross-Over Studies | 1 | 2021 | 867 | 0.17 | Why? |
| Vaginosis, Bacterial | 1 | 2017 | 51 | 0.17 | Why? |
| Neurosyphilis | 1 | 2017 | 17 | 0.17 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.17 | Why? |
| Cryptococcus neoformans | 1 | 2017 | 71 | 0.17 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.16 | Why? |
| Herpesvirus 2, Human | 1 | 2017 | 137 | 0.16 | Why? |
| Fluorescent Antibody Technique | 1 | 2019 | 835 | 0.16 | Why? |
| Helicobacter Infections | 1 | 2019 | 216 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.15 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Mammals | 1 | 2018 | 315 | 0.15 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.15 | Why? |
| Humans | 27 | 2021 | 930598 | 0.14 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.14 | Why? |
| Male | 15 | 2021 | 367725 | 0.13 | Why? |
| Invasive Fungal Infections | 1 | 2017 | 274 | 0.12 | Why? |
| Antitubercular Agents | 1 | 2019 | 775 | 0.12 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Skin | 3 | 2019 | 2096 | 0.12 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.12 | Why? |
| Adult | 10 | 2021 | 244371 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| Social Networking | 1 | 2017 | 737 | 0.11 | Why? |
| Biopsy | 1 | 2019 | 2811 | 0.10 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Double-Blind Method | 1 | 2021 | 5988 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.10 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.10 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.09 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.09 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.08 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.08 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.07 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.06 | Why? |
| Animals | 4 | 2020 | 78931 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Female | 6 | 2018 | 380317 | 0.05 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Spores, Fungal | 1 | 2017 | 23 | 0.05 | Why? |
| RNA, Ribosomal, 23S | 1 | 2017 | 25 | 0.04 | Why? |
| Blastomyces | 1 | 2017 | 6 | 0.04 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.04 | Why? |
| Ammonia | 1 | 2017 | 61 | 0.04 | Why? |
| Histoplasma | 1 | 2017 | 42 | 0.04 | Why? |
| DNA, Ribosomal | 1 | 2017 | 112 | 0.04 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 116 | 0.04 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.04 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Young Adult | 2 | 2017 | 93724 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Urea | 1 | 2017 | 228 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.04 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.04 | Why? |
| Post-Exposure Prophylaxis | 1 | 2019 | 472 | 0.04 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.04 | Why? |
| Point Mutation | 1 | 2017 | 481 | 0.03 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.03 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.03 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.03 | Why? |
| Dogs | 1 | 2019 | 2529 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.03 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.02 | Why? |
| Kinetics | 1 | 2017 | 3238 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Antibody Formation | 1 | 2019 | 4038 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Fever | 1 | 2017 | 7795 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| China | 1 | 2017 | 50654 | 0.01 | Why? |
| Lung | 1 | 2017 | 31049 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2019 | 51949 | 0.00 | Why? |
Kenyon's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(143)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_